已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Failure to use new breakthrough treatments for epilepsy

Dravet综合征 医学 癫痫 芬氟拉明 左乙拉西坦 不利影响 Lennox-Gastaut综合征 安慰剂 随机对照试验 儿科 麻醉 内科学 精神科 替代医学 血清素 受体 病理
作者
Pavel Klein,Gregory L. Krauss,Bernhard Jochen Steinhoff,Orrin Devinsky,Michael R. Sperling
出处
期刊:Epilepsia [Wiley]
卷期号:64 (6): 1458-1465 被引量:50
标识
DOI:10.1111/epi.17564
摘要

Despite the approval of ~20 additional antiseizure medications (ASMs) since the 1980s, one-third of epilepsy patients experience seizures despite therapy. Drug-resistant epilepsy (DRE) is associated with cognitive and psychiatric comorbidities, socioeconomic impairment, injuries, and a 9.3-13.4 times higher mortality rate than in seizure-free patients. Improved seizure control can reduce morbidity and mortality. Two new ASMs were launched in the United States in 2020: cenobamate for focal epilepsy in adults and fenfluramine for Dravet syndrome (DS). They offer markedly improved efficacy. Cenobamate achieved 21% seizure freedom with the highest dose and decreased tonic-clonic seizures by 93% during maintenance treatment in a randomized clinical trial (RCT). In long-term, open-label studies, 10%-36% of patients were seizure-free for a median duration of ~30-45 months. Fenfluramine treatment in DS reduced convulsive seizure frequency by 56% over placebo at the highest dose, with 8% of patients free of convulsive seizures, and 25% with only one convulsive seizure over 14 weeks. These results were sustained for up to 3 years in open-label extension studies. Mortality was reduced 5-fold. These results are superior to all other approved ASMs, placing these two drugs among the most effective antiseizure therapies. The adverse event profiles resemble those of other ASMs. Despite greater efficacy and similar toxicity, these medications are infrequently used. Two years after US market entry, < 5% of either adults with focal DRE or patients with DS were treated with either cenobamate or fenfluramine. We believe this is a failure of our medical system, resulting from limited knowledge about these drugs stemming partly from the separation of academia from industry; restrictions to access created by health care payors, hospitals, and regulatory agencies; and insufficient post-launch information about the efficacy and safety of these ASMs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
磊4165564发布了新的文献求助10
刚刚
风趣的飞阳完成签到,获得积分10
1秒前
祁琳桐完成签到,获得积分10
2秒前
3秒前
4秒前
Isaac完成签到,获得积分10
4秒前
5秒前
lailailai完成签到,获得积分10
6秒前
香蕉觅云的应助被洁净静竹采纳,获得10
6秒前
隐形曼青的应助被知有采纳,获得10
8秒前
9秒前
juan完成签到 ,获得积分10
9秒前
yu完成签到 ,获得积分0
10秒前
123456完成签到 ,获得积分10
11秒前
TOM完成签到 ,获得积分10
11秒前
风吹麦浪的应助被lailailai采纳,获得10
12秒前
13秒前
14秒前
14秒前
lucky发布了新的文献求助100
15秒前
痞老板死磕蟹黄堡完成签到 ,获得积分10
15秒前
朴实的问雁完成签到 ,获得积分10
17秒前
18秒前
洁净静竹发布了新的文献求助10
19秒前
QQ农场提示我菜死了完成签到,获得积分10
20秒前
20秒前
Raim发布了新的文献求助10
20秒前
23秒前
23秒前
彭于晏的应助被高高采纳,获得10
26秒前
zho发布了新的文献求助10
26秒前
Jayson完成签到,获得积分10
27秒前
ding的应助被知有采纳,获得10
27秒前
666完成签到 ,获得积分10
27秒前
郑朗逸完成签到,获得积分10
27秒前
28秒前
lsyjflstv关注了科研通微信公众号
30秒前
放松完成签到 ,获得积分10
30秒前
飘逸的听露完成签到 ,获得积分10
30秒前
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554296
关于积分的说明 21718786
捐赠科研通 7747941
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551811
邀请新用户注册赠送积分活动 2471194